# US 2015/0087825 A1 · Spirocyclic digydro-thiazine and dihydro-oxazine bace inhibitors, and compositions and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0087825 A1
- Document ID: US20150087825A1
- Status: Published application
- Kind: A1
- Application number: 14/556,895
- Filed: 2014-12-01
- Published: 2015-03-26
- Earliest claimed: 2012-03-20
- Inventors: Ying-Zi Xu; Dean R. Artis; Simeon Bowers; Roy K. Hom; Hing L. Sham; Shendong Yuan
- Web page: https://patentgrep.com/patent/US20150087825A1

## CPC

- C07D 513/10: Spiro-condensed systems
- A61P 21/02: Muscle relaxants, e.g. for tetanus or cramps
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07D 265/12: condensed with carbocyclic rings or ring systems
- C07D 265/18: with hetero atoms directly attached in position 2
- C07D 279/08: condensed with carbocyclic rings or ring systems
- C07D 279/16: condensed with one six-membered ring
- C07D 413/10: linked by a carbon chain containing aromatic rings
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 413/14: containing three or more hetero rings
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07D 417/14: containing three or more hetero rings
- C07D 498/10: Spiro-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compounds are provided having a structure according to Formula (I): wherein A1, A2, A3, Y, R1, R2, R3, R4, R5, R6, m, n and p are defined herein. Further provided are pharmaceutical compositions including the compounds provided and methods of making and using the compounds and compositions as provided, e.g., in the treatment and prevention of various disorders, such as Alzheimer's disease.

## Claims

### Claim 1

A compound having a structure according to Formula I:
or a pharmaceutically accept able salt thereof, wherein:
Y is O or S;
L is selected from the group consisting of a direct bond, —CR7R8—, —C(O)—, —O—, —S(O)z—, —NR9—, —CR7R8—CR10R11, —CR7R8—C(O)—, —CR7R8—O—, —CR7R8—S(O)z—, —CR7R8—NR9—, —C(O)—CR10R11—, —C(O)—O—, —C(O)—NR9—, —O—CR10R11—, —O—C(O)—, —S(O)z—CR10R11—, —S(O)2—NR9—, —NR9—CR10R11—, —NR9—C(O)—, and —NR9—S(O)2—;
A1 is a C3-10 carbocyclic ring or a 3 to 10 membered heterocyclic ring;
A2 is phenyl, naphthyl, or a heteroaryl ring;
A3 is phenyl, naphthyl, or a heteroaryl ring;
R1 is hydrogen, C1-6 alkyl, or combines with R2 to form a fused monocyclic C3-7 carbocyclic ring or a 3 to 7 membered heterocyclic ring;
R2 and R3 are independently hydrogen or halogen, or R3 is hydrogen and R2 combines with R1 to form a fused monocyclic C3-7 carbocyclic ring or a 3 to 7 membered heterocyclic ring;
R4 at each occurrence is independently selected from the group consisting of halogen, —CN, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, —OH, ═O, —OR12, —S(O)zR12, —C(O)R12, —NR13R14, and ═NR14, wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and C3-6 cycloalkyl are optionally substituted with one or more fluoro, —OH, —NH2, —ORa, —S(O)zRa, —C(O)Ra, —NHRa, —NRaRb, or optionally fluoro substituted C3-6 cycloalkyl;
R5 and R6 at each occurrence are independently selected from the group consisting of halogen, —CN, —OH, —NH2, —NO2, —C(O)—OH, —C(O)—NH2, —S(O)2—NH2, and L1-R15;
R7, R8, R9, R10, and R11 are independently selected from the group consisting of hydrogen and C1-6 alkyl;
L1 at each occurrence is independently selected from the group consisting of a direct bond, —C(O)—, —O—, —S(O)z, —NR16—, —C(O)—O—, —O—C(O)—, —C(O)—NR16—, —NR16—C(O)—, —S(O)2—NR16—, and —NR16—S(O)2—;
R12 at each occurrence is independently selected from the group consisting of C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and C3-6 cycloalkyl, wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and C3-6 cycloalkyl are optionally substituted with one or more substituents independently selected from the group consisting of fluoro, —OH, —NH2, —ORa, —S(O)zRa, —C(O)Ra, —NHRa, —NRaRb, and optionally fluoro substituted C3-6 cycloalkyl;
R13 and R14 at each occurrence are independently selected from the group consisting of hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and C3-6 cycloalkyl, wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and C3-6 cycloalkyl are optionally substituted with one or more substituents independently selected from the group consisting of fluoro, —OH, —NH2, —ORa, —S(O)zRa, —C(O)Ra, —NHRa, —NRaRb, and optionally fluoro substituted C3-6 cycloalkyl or R13 and R14 combine with the nitrogen to which they are attached to form a 4-7 membered monocyclic heterocyclic ring or a 5 or 7 membered heteroaryl ring, wherein said ring is optionally substituted with one or more substituents independently selected from the group consisting of halogen, —CN, ═O, —OH, —NH2, —ORa, —S(O)zRa, —C(O)Ra, —NHRa, —NRaRb, and optionally fluoro substituted C1-6 alkyl, optionally fluoro substituted C2-6 alkenyl, optionally fluoro substituted C2-6 alkynyl, and optionally fluoro substituted C3-6 cycloalkyl;
R15 at each occurrence is independently selected from the group consisting of C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and C3-6 cycloalkyl, 3-7 membered heterocycloalkyl, phenyl, naphthyl, and heteroaryl, wherein phenyl, naphthyl, and heteroaryl are optionally substituted with one or more substituents independently selected from the group consisting of —CN, —OH, —NO2, —C(O)—OH, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and C3-6 cycloalkyl, 3-7 membered heterocycloalkyl, phenyl, 5 or 6 membered heteroaryl, —OR17, —S(O)zR17, —NR18R19, —C(O)R17, —C(O)—OR17, —O—C(O)R17, —C(O)—NR18R19, —NR16—C(O)R17, —S(O)2—NR18R19, and —NR16—S(O)2R17, and wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and C3-6 cycloalkyl, 3-7 membered heterocycloalkyl, as R15 or as a substituent of phenyl, naphthyl, or heteroaryl, are optionally substituted with one or more substituents independently selected from the group consisting of fluoro, —CN, —OH, ═O, ═NH, —NO2, —C(O)—OH, C3-6 cycloalkyl, 3-7 membered heterocycloalkyl, —OR17, —S(O)zR17, ═NR17, —NR18R19, —C(O)R17, —C(O)—OR17, —O—C(O)R17, —C(O)—NR18R19, —NR16—C(O)R17, —S(O)2—NR18R19, and —NR16—S(O)2R17;
R16 at each occurrence is independently selected from the group consisting of hydrogen C1-6 alkyl;
R17 at each occurrence is independently selected from the group consisting of C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and C3-6 cycloalkyl, wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and C3-6 cycloalkyl are optionally substituted with one or more substituents independently selected from the group consisting of fluoro, —OH, —NH2, —ORa, —S(O)zRa, —C(O)Ra, —NHRa, —NRaRb, and optionally fluoro substituted C3-6 cycloalkyl;
R18 and R19 at each occurrence are independently selected from the group consisting of hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and C3-6 cycloalkyl, wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and C3-6 cycloalkyl are optionally substituted with one or more substituents independently selected from the group consisting of fluoro, —OH, —NH2, —ORa, —S(O)zRa, —C(O)Ra, —NHRa, —NRaRb, and optionally fluoro substituted C3-6 cycloalkyl, or R18 and R19 combine with the nitrogen to which they are attached to form a 4-7 membered monocyclic heterocyclic ring or a 5 or 7 membered heteroaryl ring, wherein said ring is optionally substituted with one or more substituents independently selected from the group consisting of halogen, —CN, ═O, —OH, —NH2, —ORa, —S(O)zRa, —C(O)Ra, —NHRa, —NRaRb, optionally fluoro substituted C1-6 alkyl, optionally fluoro substituted C2-6 alkenyl, optionally fluoro substituted C2-6 alkynyl, and optionally fluoro substituted C3-6 cycloalkyl; Ra and Rb at each occurrence are independently selected from the group consisting of optionally fluoro substituted C1-6 alkyl, optionally fluoro substituted C2-6 alkenyl, optionally fluoro substituted C2-6 alkynyl, and optionally fluoro substituted C3-6 cycloalkyl, or Ra and Rb combine with the nitrogen to which they are attached to form N-linked-heterocycloalkyl;
m is 0, 1, or 2;
n is 0, 1, 2, or 3;
p is 0, 1, 2, or 3; and
z is 0, 1, or 2.

### Claim 2 (depends on 1)

The compound of claim 1, wherein the compound has a structure according to Formula Ib:
or a pharmaceutically acceptable salt thereof, wherein:
X is O or S(O)2;
r is 0, 1, or 2;
s is 0, 1, or 2; and
A2, A3, Y, R5, R6, n and p are as defined in claim 1.

### Claim 3 (depends on 2)

The compound of claim 2, wherein X is O.

### Claim 4 (depends on 3)

The compound of claim 3, wherein the compound has the structure:
